New 5-year results of a Landmark Study confirm LINX procedure as a beneficial treatment for gastro-esophageal reflux disease (GERD). Study authors conclude LINX should be a first-line therapy option for GERD sufferers.
Torax Medical announced the completion of a landmark study confirming long-term results of the LINX® Reflux Management System in controlling reflux-related symptoms and eliminating dependence on the acid suppression medications called proton pump inhibitors (PPIs). Findings from the clinical study demonstrated that the LINX procedure normalized the amount of acid in the esophagus, while safely and effectively relieving heartburn and regurgitation, and improving quality of life without the need for PPIs. The LINX device was approved by the FDA in early 2012 and is currently the only medical device approved by the FDA to be safe and effective for the treatment of gastro-esophageal reflux disease (GERD).
Authors of the clinical study, published this week in a leading medical journal [Clinical Gastroenterology and Hepatology (http://www.cghjournal.org/article/S1542-3565(15)00763-6/abstract) concluded LINX should now be considered a first-line anti-reflux therapy for appropriate patients.